<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985957</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-650</org_study_id>
    <secondary_id>2016-001928-54</secondary_id>
    <nct_id>NCT02985957</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>CheckMate 650</acronym>
  <official_title>A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nivolumab plus ipilimumab has preliminary
      evidence of safety and effectiveness in treatment of metastatic castration-resistant prostate
      cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Anticipated">March 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 24 weeks from treatment initiation</time_frame>
    <description>measured by response assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Progression-Free Survival (rPFS)</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by radiographic/clinical progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic/Clinical Progression-Free Survival (rcPFS)</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by radiographic/clinical progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years from treatment initiation</time_frame>
    <description>measured by time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with serious adverse events</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events leading to discontinuation</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with immune-mediated adverse events</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with deaths</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with laboratory abnormalities</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with changes in pain as measured by Brief Pain Inventory-Short Form (BPI-SF)</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life- Five Dimensions (EQ-5D-3L) scores</measure>
    <time_frame>Approximately 12 months from treatment initiation</time_frame>
    <description>measured by assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Second Generation Hormone Therapies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asymptomatic or minimally symptomatic subjects who have progressed after second generation hormone therapies and have not been treated with chemotherapy
Subjects will be treated with nivolumab in combination with ipilimumab followed by nivolumab monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytotoxic Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with progression after taxane-based chemotherapy
Subjects will be treated with nivolumab in combination with ipilimumab followed by nivolumab monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Second Generation Hormone Therapies</arm_group_label>
    <arm_group_label>Cytotoxic Chemotherapy</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Second Generation Hormone Therapies</arm_group_label>
    <arm_group_label>Cytotoxic Chemotherapy</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Metastatic, castrate resistant prostate cancer (M1 by National Comprehensive Cancer
             Network (NCCN) criteria)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone
             (GnRH) analogue or a surgical/medical castration with testosterone level of
             ≤1.73nmol/L (50ng/dL)

          -  Patients with skeletal system symptoms who are already on medications to strengthen
             bones are allowed if they were started ˃28 days before study treatment

          -  Bone-directed radiotherapy to pelvic region for ease of pain from painful bone
             metastases is allowed up to 14 days before

        Exclusion Criteria:

          -  Cancer that has spread to the liver or brain

          -  Active, known, or suspected autoimmune disease or infection

          -  Prior treatment with any drug that targets T cell co-stimulation pathways(such as
             checkpoint inhibitors)

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akash Patnaik, Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School Of Medicine At Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Galsky, Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Narayan, Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

